TORONTO, June 6 /PRNewswire/ - Archimed, the woundcare division of Insense Ltd., today announced it has received approval from Health Canada for the use of its revolutionary Oxyzyme product in the treatment of difficult and chronic wounds. Oxyzyme was first trialed in Toronto by Dr. Gary Sibbald, one of the world's leading wound care specialists, in 2004 by his team at the Toronto Wound Healing Centres. The announcement was made at the 3rd Congress of the World Union of Wound Healing Societies taking place from June 4-8, 2008 at the Metro Toronto Convention Center.
Oxyzyme is a biochemical system in a dressing that ensures the oxygen in the wound environment meets the diverse oxygen needs of the cells responsible for healing. Ongoing clinical programs being undertaken in Europe are showing that 20% of old, previously unhealable wounds (3.5 years) are now closing in six weeks or under when dressed with Oxyzyme. Easy to use by any clinical professional, Oxyzyme will now soon be available to the Canadian health care system at a modest cost.
In conjunction with the announcement, Professor T.K. Hunt, often cited as the father of modern wound care, was awarded a lifetime achievement award by the World Union of Wound Healing Societies. Professor Hunt's insight and discoveries on the role oxygen plays in the healing process was the inspiration behind the development of Oxyzyme.
"The real value of Oxyzyme is that it combines two agents - iodine and
oxygen - that are essential to the process of wound healing and provides
further opportunities to overcome barriers to healing that may exist in the
patient," explained Dr. Keith Harding, leading figure in the international
wound care community and also a member of the World Union faculty.
For more information about Oxyzyme and Archimed visit http://www.archimed.co.uk.
About Insense Ltd.
------------------ Insense is a Brit
|SOURCE Insense Ltd.|
Copyright©2008 PR Newswire.
All rights reserved